Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells

Fig. 5

POG inhibits the immunosuppressive capacity of PMN-MDSCs without affecting the function of T-lymphocytes in vitro. a-b Results of the metabolomics analysis of B16-F10 tumour-bearing PMN-MDSCs after POG treatment. c qRT-PCR detection of the effect of POG on iNOS and Arg-1 expression levels of PMN-MDSCs. d Western blot analysis of the effect of POG on iNOS and Arg-1 expression levels in PMN-MDSCs. e-g Effect of POG on ARG1 activity (E), ROS (F) and NO (g) production of the PMN-MDSCs. h Effect of POG on the ability of PMN-MDSCs to inhibit the proliferation of CD8 T-lymphocytes. i Effect of POG on the IFN-γ content in CD8 T-lymphocytes. The pooled data from three independent experiments are shown. All data are represented as the mean ± SD. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page